Automated linguistic analysis in youth at clinical high risk for psychosis.

Journal: Schizophrenia research
PMID:

Abstract

Identifying individuals at clinical high risk for psychosis (CHRP) is crucial for preventing psychosis and improving the prognosis for schizophrenia. Individuals at CHR-P may exhibit mild forms of formal thought disorder (FTD), making it possible to identify them using natural language processing (NLP) methods. In this study, speech samples of 62 CHR-P individuals and 45 healthy controls (HCs) were elicited using Thematic Apperception Test images. The evaluation involved various NLP measures such as semantic similarity, generic, and part-of-speech (POS) features. The CHR-P group demonstrated higher sentence-level semantic similarity and reduced mean image-to-text similarity. Regarding generic analysis, they demonstrated reduced verbosity and produced shorter sentences with shorter words. The POS analysis revealed a decrease in the utilization of adverbs, conjunctions, and first-person singular pronouns, alongside an increase in the utilization of adjectives in the CHR-P group compared to HC. In addition, we developed a machine-learning model based on 30 NLP-derived features to distinguish between the CHR-P and HC groups. The model demonstrated an accuracy of 79.6 % and an AUC-ROC of 0.86. Overall, these findings suggest that automated language analysis of speech could provide valuable information for characterizing FTD during the clinical high-risk phase and has the potential to be applied objectively for early intervention for psychosis.

Authors

  • Elif Kizilay
    Department of Neurosciences, Health Sciences Institute, Dokuz Eylul University, Izmir, Turkey. Electronic address: elif.irem.kizilay@gmail.com.
  • Berat Arslan
    Department of Neurosciences, Health Sciences Institute, Dokuz Eylul University, Izmir, Turkey.
  • Burcu Verim
    Department of Neurosciences, Health Sciences Institute, Dokuz Eylul University, Izmir, Turkey.
  • Cemal Demirlek
    Department of Neurosciences, Health Sciences Institute, Dokuz Eylul University, Izmir, Turkey; Department of Psychiatry, McLean Hospital, Harvard Medical School, Belmont, MA, USA.
  • Muhammed Demir
    Department of Neurosciences, Health Sciences Institute, Dokuz Eylul University, Izmir, Turkey.
  • Ezgi Cesim
    Department of Neurosciences, Health Sciences Institute, Dokuz Eylul University, Izmir, Turkey.
  • Merve Sumeyye Eyuboglu
    Department of Neurosciences, Health Sciences Institute, Dokuz Eylul University, Izmir, Turkey.
  • Simge Uzman Ozbek
    Department of Psychiatry, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey.
  • Ekin Sut
    Department of Child and Adolescent Psychiatry, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey.
  • Berna Yalincetin
    Department of Neurosciences, Health Sciences Institute, Dokuz Eylul University, Izmir, Turkey.
  • Emre Bora
    Department of Neurosciences, Health Sciences Institute, Dokuz Eylul University, Izmir, Turkey; Department of Psychiatry, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey; Department of Psychiatry, Melbourne Neuropsychiatry Centre, University of Melbourne and Melbourne Health, Carlton South, Victoria 3053, Australia.